Optical Dosimeter-guided Photodynamic Therapy

Information

  • Research Project
  • 9654717
  • ApplicationId
    9654717
  • Core Project Number
    R44CA213607
  • Full Project Number
    5R44CA213607-03
  • Serial Number
    213607
  • FOA Number
    PA-17-302
  • Sub Project Id
  • Project Start Date
    1/1/2017 - 8 years ago
  • Project End Date
    2/29/2020 - 4 years ago
  • Program Officer Name
    EVANS, GREGORY
  • Budget Start Date
    3/1/2019 - 5 years ago
  • Budget End Date
    2/29/2020 - 4 years ago
  • Fiscal Year
    2019
  • Support Year
    03
  • Suffix
  • Award Notice Date
    2/15/2019 - 5 years ago
Organizations

Optical Dosimeter-guided Photodynamic Therapy

Project Summary/Abstract Photodynamic Therapy (PDT) is a promising modality for cancer treatment. Typically, a laser is used to photo-excite a photosensitizer (PS) that subsequently collides with oxygen molecules promoting them to the metastable singlet delta state O2(1?). Singlet oxygen molecules are believed to be the species that destroys cancerous cells during PDT. Despite the benefit of targeted PDT that kills tumors selectively with minimum effect on surrounding healthy tissues, at the present time it is difficult, if not impossible, to predict the response of an individual to PDT. This has inhibited the acceptance of PDT for clinical uses. In this Phase II SBIR, Physical Sciences Inc. (PSI) proposes to extend the successful Phase I results and develop a 2D imaging sensor for PS fluorescence and singlet oxygen luminescence. Under previous NCI SBIR funding, PSI has developed, early prototype, in vivo capable dosimeters for PDT. These devices required pulsed lasers and temporally gated detectors. The overall goal of our proposed program is to produce an integrated, imaging PDT dosimeter that will enable real-time feedback to control PDT light dose during the treatment. In Phase I, we demonstrated a newly introduced 2D, near infrared imaging camera and obtained simultaneous in-vivo images of singlet oxygen and the photosensitizer. Based on the Phase I results, we have developed a strategy for singlet oxygen and photosensitizer dosimetry that can be used with conventional, continuous wave (cw) PDT excitation sources. In Phase II the combined PDT system will be designed, built, and extensively tested for performance verification by in vitro and in vivo studies. These studies will be completed in collaboration with Dartmouth College, our Phase I and Phase II partner. An accurate dosimeter to optimize the individual treatment response of PDT is necessary to improve the outcomes of PDT in a clinical environment. A fully developed instrument will be a valuable tool, first for PDT researchers and subsequently for clinical PDT uses.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    520193
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:520193\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHYSICAL SCIENCES, INC
  • Organization Department
  • Organization DUNS
    073800062
  • Organization City
    ANDOVER
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    018101022
  • Organization District
    UNITED STATES